Evidence map›Paper›PMID 32661307›Full record

ArticleNature biomedical engineering2020

Gold/alpha-lactalbumin nanoprobes for the imaging and treatment of breast cancer.

Jiang Yang, Tai Wang, Lina Zhao, Vinagolu K Rajasekhar, Suhasini Joshi, Chrysafis Andreou, Suchetan Pal, Hsiao-Ting Hsu, Hanwen Zhang, Ivan J Cohen and 8 more

Open access · greenAbstract read
In one paragraph

Article in Nature biomedical engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 93 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. In vivo molecular imaging in preclinical research.Laboratory animal research · 2022
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Jiang YangCenter for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tai WangChemical Biology Program, Sloan Kettering Institute, New York, NY, USA.ORCID http://orcid.org/0000-0001-9984-9634
Lina ZhaoCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.ORCID http://orcid.org/0000-0002-9796-0221
Vinagolu K RajasekharDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Suhasini JoshiChemical Biology Program, Sloan Kettering Institute, New York, NY, USA.
Chrysafis AndreouCenter for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3464-9110
Suchetan PalCenter for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hsiao-Ting HsuCenter for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hanwen ZhangCenter for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ivan J CohenCenter for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ruimin HuangCenter for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ronald C HendricksonProteomics and Microchemistry Core Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matthew M MieleProteomics and Microchemistry Core Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7495-2133
Wenbo PeiChemical Biology Program, Sloan Kettering Institute, New York, NY, USA.
Matthew B BrendelMolecular Cytology Core Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3417-4597
John H HealeyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gabriela ChiosisChemical Biology Program, Sloan Kettering Institute, New York, NY, USA.ORCID http://orcid.org/0000-0003-0486-6920
Moritz F KircherCenter for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, USA. moritz_kircher@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-1575-1467
Memorial Sloan Kettering Cancer Center · USKettering University · USBrigham and Women's Hospital · USChinese Academy of Sciences · CN

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
Tumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI RIVIERI, ISABELLE · 2000 to 2015
$29.9M
Project 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7M
Ultrabright Theranostic SERRS Nanoparticles for Gastrointestinal EndoscopyR01CA222836 · NCI · STANFORD UNIVERSITY · PI ROGALLA, STEPHAN · 2018 to 2023
$3.4M
Biomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9M
MRI-Photoacoustic-Raman Nanostars for Pre- and Intraoperative Multimodal ImagingR01EB017748 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI KIRCHER, MORITZ FLORIAN · 2014 to 2017
$1.6M
Interactions of Stress and NicotineK08DA016396 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERMAN, JOSHUA A · 2005 to 2009
$866k
LTQ-ORBITRAP VELOS Tandem Mass SpectrometerS10OD010598 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI HENDRICKSON, RONALD CHARLES · 2012 to 2012
$460k
NCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA086438NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA172546NCI NIH HHS R01 CA222836NIBIB NIH HHS R01 EB017748NIDA NIH HHS K08 DA016396NIH HHS S10 OD010598
6 · The paper itself

Abstract

Theranostic agents should ideally be renally cleared and biodegradable. Here, we report the synthesis, characterization and theranostic applications of fluorescent ultrasmall gold quantum clusters that are stabilized by the milk metalloprotein alpha-lactalbumin. We synthesized three types of these nanoprobes that together display fluorescence across the visible and near-infrared spectra when excited at a single wavelength through optical colour coding. In live tumour-bearing mice, the near-infrared nanoprobe generates contrast for fluorescence, X-ray computed tomography and magnetic resonance imaging, and exhibits long circulation times, low accumulation in the reticuloendothelial system, sustained tumour retention, insignificant toxicity and renal clearance. An intravenously administrated near-infrared nanoprobe with a large Stokes shift facilitated the detection and image-guided resection of breast tumours in vivo using a smartphone with modified optics. Moreover, the partially unfolded structure of alpha-lactalbumin in the nanoprobe helps with the formation of an anti-cancer lipoprotein complex with oleic acid that triggers the inhibition of the MAPK and PI3K-AKT pathways, immunogenic cell death and the recruitment of infiltrating macrophages. The biodegradability and safety profile of the nanoprobes make them suitable for the systemic detection and localized treatment of cancer.

Indexed as

AnimalsApoptosisBreast NeoplasmsCell DeathFemaleGoldHeterograftsLactalbuminLipoproteinsMagnetic Resonance ImagingMiceMice, Inbred BALB CMitogen-Activated Protein Kinase KinasesNanotechnologyOptical ImagingPhosphatidylinositol 3-KinasesGoldLactalbuminLipoproteinsMitogen-Activated Protein Kinase KinasesPhosphatidylinositol 3-Kinases

Identifiers

PMID32661307
PMCPMC8255032
OpenAlexW3040882542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.